How Do Allergy Shots Work? The Immune Cascade Explained

The 3-5 year requirement is a biological necessity, not an arbitrary guideline. The immune tolerance SCIT produces requires three sequential processes that each take time to establish. First, regulatory T-cell populations must expand and stabilize — a process that takes months. Second, IgG4 blocking antibodies must accumulate to functionally competitive levels with IgE, which takes 3-12 months of maintenance dosing. Third, and most critically, long-lived plasma cells producing IgG4 must migrate to bone marrow niches where they survive without further antigen stimulation — a consolidation process requiring sustained allergen exposure over multiple years. The GRASS trial (Scadding et al., JAMA 2017) demonstrated that 2-year courses are insufficient: neither 2 years of SCIT nor SLIT showed significant benefit at 1-year post-treatment follow-up versus placebo. Three years is the confirmed minimum, with some evidence that 4-5 years extends post-treatment benefit further.

IgE and IgG4 are both antibodies produced by B cells, but they play opposite roles in the allergic response. IgE — the pathological antibody in allergic disease — binds permanently to receptors (FcεRI) on mast cells and basophils. When allergen molecules bridge two IgE antibodies on the same mast cell, the cell degranulates: releasing histamine, leukotrienes, and prostaglandins that cause itching, swelling, sneezing, and bronchoconstriction. IgG4 — the protective antibody produced by allergy shots — works by competing with IgE to bind allergen molecules before they reach mast cells. When IgG4 captures allergen in circulation, it cannot cross-link IgE receptors; the mast cell does not fire. Over 3-12 months of SCIT, IgG4 levels rise 10- to 100-fold, shifting the competitive balance decisively toward tolerance. The ratio of allergen-specific IgE to IgG4 falling is the immunological signature of successful desensitization.

The core molecular mechanism — Treg expansion, IgG4 rise, mast cell desensitization — is shared across all allergens treated with SCIT. However, the clinical evidence for efficacy varies substantially by allergen type, reflecting differences in extract standardization, study quality, and inherent immunogenicity. Grass pollen and dust mites have the strongest evidence base, with multiple Cochrane reviews confirming 29-85% symptom reduction. Ragweed and cat dander are well-established. Birch and Alternaria mold have moderate evidence. Dog dander has weaker evidence, partly because US dog extracts are not FDA-standardized and Can f 1 content varies 100-fold between products. Cockroach SCIT failed its primary clinical endpoint in the most rigorous recent trial (CRITICAL, JACI 2024) despite producing strong IgG4 responses — suggesting that mechanisms other than IgE-mediated allergy may drive cockroach sensitivity in inner-city asthma populations.

Regulatory T cells (Tregs) are a specialized subset of CD4+ T cells that function as the immune system's peacekeepers. They produce IL-10, TGF-beta, and IL-35 — cytokines that actively suppress immune activation. In allergic disease, Treg numbers and function are reduced relative to Th2 inflammatory cells, tipping the immune balance toward reactivity. Allergy shots shift this balance by stimulating the expansion of allergen-specific FOXP3+ CD25+ Tregs in lymph nodes draining the injection site. These Tregs then circulate systemically, suppress Th2 cytokine production (IL-4, IL-5, IL-13), reduce the inflammatory milieu in mucosal tissues, and direct B cells toward the IgG4 class switch. The Treg expansion — detectable in blood by 2-4 weeks of build-up — is one of the earliest and most important immunological markers of successful SCIT induction, confirmed in landmark studies by Akdis and colleagues at the Swiss Institute of Allergy and Asthma Research.

The core molecular mechanism is shared between SCIT and sublingual immunotherapy (SLIT): both routes induce FOXP3+ Treg expansion, IL-10 production, IgE-to-IgG4 class switching, and mast cell desensitization. What differs is the antigen-presenting cell population engaged at the entry site. SCIT allergen is captured by dermal myeloid dendritic cells that traffic to draining lymph nodes — a pathway with higher systemic exposure and greater anaphylaxis risk. SLIT allergen is captured by oral mucosal Langerhans-like dendritic cells that are constitutively pre-programmed toward tolerogenic IL-10 production and exist in an environment with low local mast cell density — which explains SLIT's dramatically better safety profile despite requiring 50-100 times higher allergen doses to achieve equivalent efficacy. Network meta-analyses (Nelson et al., JACI In Practice 2015) show comparable clinical outcomes for grass pollen and dust mites via either route.

The clearest sign that allergy shots are working is reduced symptom severity during allergen exposure — less sneezing, nasal congestion, eye itching, and asthma symptoms during the seasons or situations that previously triggered reactions. Most patients notice this improvement gradually over 3-6 months of maintenance dosing, with progressive improvement continuing into years two and three. Immunologically, IgG4 levels rising (measurable by blood test) and positive skin-test reactions becoming smaller or less reactive over time are objective markers of desensitization. If no clinical improvement is evident after 12 full months at the maintenance dose, the AAAAI/ACAAI Practice Parameter recommends reassessing allergen selection, dosing adequacy, and whether SCIT is the right approach. Subtherapeutic dosing and missed allergens are the most common causes of treatment failure, not failure of the underlying mechanism.

The persistence of benefit after stopping allergy shots — documented for 3-12 years in clinical studies — stems from long-lived plasma cells and memory Treg populations established during treatment. When the IgE-to-IgG4 class switch occurs in allergen-specific B cells under IL-10 instruction from Tregs, the most successful IgG4-producing B cell clones differentiate into long-lived plasma cells that migrate to bone marrow niches. There, they survive for years to decades without requiring further allergen stimulation, continuously secreting low-level protective IgG4. Memory Tregs similarly persist and respond rapidly to allergen re-encounter, maintaining peripheral tolerance. Durham et al. (NEJM 1999) confirmed that patients who completed 3-4 years of grass pollen SCIT showed no significant relapse for at least 3 years after stopping, with symptom scores indistinguishable from patients who continued active maintenance.